Meniere's DiseaseMANAGEMENT

ENT AND MAXILLOFACIAL PRESENTATIONS · 12 SECTIONS

⚲

468 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

ENT and Maxillofacial Presentations27▾

Acute laryngitis Acute pharyngitis Auricular hematoma Bezold's Abscess Cerumen impaction Dry socket Ear foreign body Epistaxis (anterior)Epistaxis (Posterior)Labyrinthitis Ludwig's Angina Malignant Otitis Externa Marcus Gunn Pupil Mastoiditis Meniere's Disease Nasal Bone Fracture Nasal foreign body Nasal Septal Hematoma Otitis externa Otitis Media Post-tonsillectomy hemorrhage Sialolithiasis and sialadenitis Sinusitis Sudden Sensorineural Hearing Loss TMJ dislocation Tympanic membrane perforation Vestibular Neuronitis

Ophthalmologic Presentations19▾

Obstetric Presentations23▾

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp34

Red flags requiring urgent escalation

›Central cause exclusion priorities

›New focal neurologic deficits (dysarthria, dysphagia, diplopia, limb weakness)

›Persistent vertigo >24 hours with severe imbalance

›Direction-changing or vertical nystagmus

›Abnormal HINTS exam suggesting central pathology

›Skew deviation on cover-uncover test

›Immediate imaging triggers

›Abnormal HINTS exam in acute vestibular syndrome

›Focal neurologic deficits on exam

›New severe headache with vertigo in young patient

›Concern for vertebral artery dissection or posterior fossa stroke

›Cardiac mimics requiring ECG

›Syncope or presyncope accompanying dizziness

›Drop attacks (Tumarkin crises) — exclude cardiac syncope

›Prolonged QTc, Brugada pattern, or heart block on ECG

Stabilization and monitoring

›Acute attack management priorities

›IV access and antiemetic therapy for nausea and vomiting

›IV fluids if dehydrated from repeated vomiting

›Cardiac monitor if syncope or arrhythmia concern

›SpO2 monitoring with supplemental oxygen if needed

›Dark, quiet room with minimal head movement

›Escalation triggers

›Intractable vomiting unresponsive to antiemetics

›Inability to ambulate safely — fall risk

›Persistent hemodynamic instability suggesting non-Meniere etiology

›Inability to exclude central cause — neurology consult and MRI

02History/hx49

Symptom characterization

›Vertigo features

›True rotational vertigo — not lightheadedness or presyncope

›Episode duration 20 minutes to 12 hours (hallmark of definite MD)

›Frequency of attacks (average 6–11 attacks per year)

›Spontaneous onset without positional trigger

›Aural symptoms

›Unilateral sensorineural hearing loss — often low-frequency initially

›Tinnitus quality and laterality (ringing or buzzing)

›Aural fullness or pressure sensation

›Fluctuation of hearing and aural symptoms clustering with vertigo episodes

Associated symptoms and alarm features

›Associated symptoms

›Nausea and vomiting during attacks

›Postural instability between attacks

›Drop attacks (Tumarkin crises — sudden falls without loss of consciousness)

›Important negatives

›No loss of consciousness — LOC is never a symptom of MD

›No focal neurologic deficits

›No headache or photophobia (suggests vestibular migraine if present)

›No otalgia or otorrhea

Risk factors and triggers

›Established risk factors

›Age 40–60 (peak incidence); biphasic occurrence with secondary peak in 20s

›Slight female predominance

›Migraine history — at least twice as likely in MD patients

›Autoimmune disease (immune-mediated inner ear pathology)

›Allergies and atopy — proposed association

03Physical Exam/exam37

Otoscopy and hearing assessment

›Otoscopic findings

›Typically normal tympanic membranes in MD

›Middle ear effusion — alternative diagnosis

›Cholesteatoma or tympanic membrane perforation — alternative diagnoses

›Bedside hearing assessment

›Weber test: lateralizes to unaffected ear in unilateral SNHL

›Rinne test: air conduction greater than bone conduction bilaterally — consistent with SNHL

›Whispered voice test for gross hearing assessment

Nystagmus and HINTS exam

›Nystagmus characterization

›Acute attack: unidirectional horizontal nystagmus beating away from affected ear

›Between attacks: nystagmus may be absent

›Direction-changing nystagmus — central cause concern

›Vertical nystagmus — central cause concern

›HINTS exam components

›Head Impulse Test: normal = no corrective saccade (central concern); abnormal = corrective saccade (peripheral)

›Nystagmus: direction-fixed (peripheral); direction-changing (central)

›Test of Skew: positive skew deviation indicates central pathology

›HINTS exam sensitivity 100% and specificity 96% for central cause in acute vestibular syndrome

Neurological and vestibular exam

›Cranial nerve assessment

›Full cranial nerve exam to exclude CPA tumor or brainstem pathology

›Facial nerve function

›Soft palate and gag (IX, X)

›Cerebellar examination

›Finger-to-nose testing

›Heel-to-shin testing

04Differential Diagnosis/ddx43

Peripheral vestibular disorders

›Benign paroxysmal positional vertigo (BPPV) — H81.10

›Positional vertigo lasting seconds (not minutes to hours)

›No hearing loss or tinnitus

›Positive Dix-Hallpike with fatigable nystagmus

›Vestibular neuritis — H81.20

›Single prolonged episode lasting 12–36 hours

›No hearing loss (distinguishes from labyrinthitis)

›Abnormal head impulse test (corrective saccade)

›Labyrinthitis — H83.09

›Sudden severe vertigo with profound hearing loss

›Not episodic or fluctuating — single event

›Often preceded by viral URI

Central causes (must exclude)

›Posterior fossa stroke or TIA — I63.9

›Focal neurologic deficits present

›Non-fluctuating; deficits are persistent

›Abnormal HINTS exam (normal HIT, direction-changing nystagmus, skew deviation)

›Vestibular migraine — G43.D0

›Attacks may be 20 minutes to >24 hours (overlapping duration)

›Photophobia and phonophobia distinguish from MD

›Hearing loss mild or absent and stable (not fluctuating SNHL)

›Migraine history present

›Vertebral artery dissection — I77.74

›New severe headache with vertigo in young patient

›Risk factors: neck manipulation, trauma, connective tissue disorder

Structural and other causes

›Vestibular schwannoma (CPA tumor) — D33.3

05Laboratory Tests/lt18

Exclusionary labs

›Basic workup to exclude mimics

›Complete blood count — anemia or infection contributing to symptoms

›Basic metabolic panel — electrolytes, glucose, renal function

›TSH — thyroid dysfunction can cause dizziness

›No specific lab test diagnoses Meniere's disease

Infectious and inflammatory screening

›Syphilis serology

›RPR or VDRL screening test

›FTA-ABS confirmatory test (especially if bilateral or atypical presentation)

›Sensitivity of RPR for syphilis approximately 78% in primary, 100% in secondary

›Autoimmune and inflammatory panel

›ESR and CRP if autoimmune inner ear disease suspected

›ANA if systemic autoimmune features present

›Lyme serology in endemic areas

Monitoring labs for treatment

›Diuretic therapy monitoring

›Potassium level — hypokalemia risk with HCTZ

›Sodium level

›Creatinine — renal function baseline and monitoring

›Electrolyte recheck 4–6 weeks after diuretic initiation

06Diagnostic Tests/dt53

Scoring Systems

›Diagnostic criteria — AAO-HNS 2020

›Definite Meniere's disease: >=2 spontaneous vertigo episodes (20 min–12 hr) + audiometrically confirmed SNHL + fluctuating aural symptoms (hearing, tinnitus, or fullness) + no better alternative diagnosis

›Probable Meniere's disease: >=2 spontaneous vertigo episodes (20 min–24 hr) + fluctuating aural symptoms + no better alternative diagnosis (audiometry not required)

›Unilateral disease initially in most cases; up to 50% develop bilateral involvement over decades

›HINTS exam for central cause exclusion

›Head Impulse normal + direction-changing Nystagmus + positive Test of Skew = HINTS positive = central

›Sensitivity 100% for central cause; specificity 96%

›Superiority to MRI in first 24–48 hours of acute vestibular syndrome for stroke detection

›ACEP endorses HINTS as high-value bedside tool

MRI

›MRI brain and internal auditory canals with and without contrast

›Primary indication: asymmetric SNHL to exclude vestibular schwannoma or CPA pathology

›Gadolinium-enhanced sequences required for CPA mass detection

›Sensitivity of MRI for vestibular schwannoma >95%

›ACR Appropriateness Criteria 2023: MRI brain and IAC recommended for asymmetric SNHL

›MRI with 3D FLAIR endolymphatic hydrops imaging

›Gadolinium-enhanced 3D-FLAIR sequences can demonstrate endolymphatic hydrops

›Research and specialty use; not routine in ED or primary care

›4-hour delayed imaging after IV gadolinium improves hydrops detection

›Sensitivity 78–89% for endolymphatic hydrops in confirmed MD

›MRI posterior fossa for central cause exclusion

›Indicated when HINTS exam is positive or focal deficits present

›DWI sequences essential for acute stroke detection

›MRI superior to CT for posterior fossa pathology

›CT temporal bone without contrast

›Indication: suspected superior semicircular canal dehiscence

›High-resolution protocol required (0.6 mm slices)

›Dehiscence visible as focal absence of bone over superior canal

›Not indicated for routine Meniere's disease evaluation

›CT head without contrast

›Indicated when MRI not immediately available and central cause suspected

›Sensitivity for acute posterior fossa hemorrhage acceptable

›Sensitivity for posterior fossa ischemic stroke low within 24 hours (<50%)

›Not the preferred imaging modality for acute vestibular syndrome

›ACR Appropriateness Criteria 2023

›CT head usually not appropriate for isolated dizziness without neurologic deficits

›CT may be appropriate when MRI unavailable and central cause suspected

Ultrasound

›No primary role for ultrasound in Meniere's disease diagnosis

›Utility limited — inner ear structures not accessible to standard ultrasound

›Carotid and vertebral ultrasound relevant if vascular etiology of dizziness suspected

›Transcranial Doppler: research application for vertebrobasilar flow assessment

›Cardiac ultrasound (echocardiography)

›Indicated if embolic source or cardiac cause of recurrent dizziness considered

›Not part of routine MD evaluation

Audiometry

›Pure-tone audiometry — gold standard initial test

›AAO-HNS strong recommendation for audiogram in all suspected MD

›Low- to mid-frequency SNHL pattern characteristic (250–2000 Hz)

›Fluctuating SNHL on serial audiograms supports diagnosis

›Required for definite MD diagnosis under AAO-HNS 2020 criteria

›Special vestibular function tests

›Electrocochleography (ECoG): elevated summating potential to action potential ratio (SP/AP >0.4) supports endolymphatic hydrops; optional and adjunctive

›Videonystagmography (VNG) or electronystagmography (ENG): may show unilateral caloric weakness; not routinely required for diagnosis

›Vestibular evoked myogenic potentials (VEMPs): adjunctive; may be abnormal in MD but not diagnostic

›AAO-HNS recommends against routinely ordering vestibular function testing or ECoG to establish the diagnosis

07Disposition/dispo25

Discharge criteria

›Safe for discharge when

›Symptoms improving or resolved

›Tolerating oral intake

›Able to ambulate safely without fall risk

›Reliable follow-up arranged

›Central cause excluded clinically or radiographically

›Discharge planning

›ENT or otolaryngology referral arranged — all new suspected MD

›Audiology referral for formal audiometric testing

›Prescription for vestibular suppressant for outpatient acute attack management

›Driving restriction counseling during active vertigo

Admission and observation indications

›Criteria for admission or extended observation

›Intractable vomiting and dehydration unresponsive to IV antiemetics

›Inability to ambulate safely — high fall risk, particularly elderly

›Cannot exclude central cause — admit for MRI and neurology consultation

›New-onset drop attacks (Tumarkin crises) requiring evaluation

›Syncope accompanying dizziness — cardiac monitoring

›Specialist consultation triggers

›Neurology: if central cause cannot be excluded

›ENT/Otolaryngology: new suspected MD or known MD with new features

›Audiology: formal audiometric testing for definitive diagnosis

Transfer criteria

›Transfer to higher-level care when

›MRI confirms posterior fossa stroke — transfer to stroke center

›CPA mass identified — neurosurgery consultation

›Intractable disease requiring intratympanic procedures not available at current facility

08Treatment/t68

Acute attack management — ED

›Vestibular suppressants

›Meclizine 25–50 mg PO every 6 hours as needed

›First-line antihistamine vestibular suppressant

›Sedating; useful for inpatient or short-term use

›Dimenhydrinate 50 mg PO or IV every 6 hours as needed

›IV formulation available for patients unable to tolerate oral medications

›Diazepam 2–5 mg IV for severe refractory vertigo

›Short-term only — impairs central vestibular compensation with prolonged use

›Risk of respiratory depression; monitor carefully

›Antiemetic therapy

›Ondansetron 4–8 mg IV or ODT — first-line for nausea

›Onset 5–10 minutes IV

›Minimal sedation

›Promethazine 12.5–25 mg IV, IM, or PR for severe nausea

›Monitor for extrapyramidal effects

›Avoid in elderly — high anticholinergic burden

›Supportive care

›IV normal saline fluid resuscitation if dehydrated

›Dark, quiet environment with minimal head movement

›Cardiac monitor if syncope or arrhythmia concern

Maintenance therapy — outpatient stepwise approach

›Lifestyle and dietary modifications (first-line)

›Sodium restriction to <1,500–2,300 mg per day

›Cochrane review 2018: no high-quality evidence supporting dietary sodium restriction, but widely recommended as low-risk first-line measure

›Caffeine reduction — may affect inner ear blood flow via vasoconstriction

›Alcohol limitation to <=1 drink per day

›Consistent fluid intake — avoid large daily fluctuations

›Stress management and adequate sleep

›Diuretic therapy (AAO-HNS: option level recommendation)

›Hydrochlorothiazide/triamterene 37.5/25 mg orally once daily

›Most commonly prescribed diuretic combination for MD

›Monitor potassium, sodium, and creatinine at baseline and 4–6 weeks

›Goal: reduce endolymphatic fluid volume and attack frequency

›Cochrane 2023: insufficient evidence from RCTs to confirm efficacy

›Betahistine (AAO-HNS: option level recommendation)

›Betahistine 16–48 mg three times daily

›Not FDA-approved in the United States

›Widely used in Europe and internationally

›Proposed mechanism: histamine H3 antagonist improving inner ear microcirculation

›Cochrane 2023: current evidence insufficient to determine efficacy definitively

Refractory disease — interventional

›Intratympanic corticosteroids

›Intratympanic dexamethasone 4–24 mg/mL injection

›Indicated for active disease not responsive to noninvasive treatment

›Hearing-sparing procedure

›3–4 injections over 2 weeks typical protocol

›AAO-HNS: option level recommendation

›Intratympanic gentamicin (ablative)

›Gentamicin 26.7 mg/mL intratympanic injection

›Indicated for refractory unilateral MD with disabling vertigo

›Selective vestibulotoxic effect reduces endolymphatic hydrops mechanism

›Risk of additional hearing loss — 15–30% rate of worsening SNHL

›AAO-HNS: option level recommendation for refractory disease

›Surgical options (specialist-only)

›Endolymphatic sac decompression — hearing-sparing; vertigo control in 60–70%

›Vestibular nerve section — high vertigo control rate (90%); hearing-sparing

›Labyrinthectomy — hearing-ablative; reserved for non-functional hearing; last resort

Medications to avoid

›Contraindicated or cautioned medications

›Chronic vestibular suppressants — impair central vestibular compensation

›Systemic aminoglycosides — ototoxic; avoid in MD patients

›Loop diuretics at high doses — cochleotoxic

›Benzodiazepines for prolonged use — suppress vestibular adaptation

Adjunctive therapies

›Vestibular rehabilitation

›Vestibular physical therapy for chronic imbalance between attacks

›Not indicated during acute attacks

›Improves postural stability and central compensation

›Hearing and psychosocial support

›Hearing aids and assistive technology counseling for progressive SNHL

›Cognitive behavioral therapy or counseling for anxiety and depression comorbidity

›Support groups and symptom diary keeping

09Special Populations/sp45

Pregnancy

›Physiologic considerations

›Hormonal fluctuations during pregnancy may influence endolymphatic fluid balance

›Sodium and fluid retention in pregnancy can exacerbate MD symptoms

›Progesterone elevation may have natriuretic effects — variable impact

›Medication safety

›Meclizine: Category B — generally considered safe in pregnancy; limited data

›Dimenhydrinate: Category B — commonly used for pregnancy-related nausea; acceptable short-term

›Ondansetron: Category B — widely used for hyperemesis; generally safe

›Diazepam: Category D — avoid in pregnancy; neonatal withdrawal and cleft palate risk

›Promethazine: use with caution; neonatal respiratory depression near delivery

›Management approach

›Diuretics contraindicated in pregnancy — risk of fetal growth restriction

›Betahistine: insufficient safety data in pregnancy — avoid

›Intratympanic dexamethasone: limited data; local delivery preferred over systemic if intervention required

›ENT and maternal-fetal medicine co-management recommended

Geriatric

›Age-related physiologic changes

›Reduced renal clearance alters drug pharmacokinetics and increases electrolyte disturbance risk

›Polypharmacy increases risk of drug interactions

›Baseline gait and balance deficits increase fall risk significantly

›Age-related hearing loss (presbycusis) confounds audiometric interpretation

›Risk stratification

›Fall risk assessment mandatory — Meniere's attacks dramatically increase fracture risk in elderly

›Tumarkin drop attacks particularly dangerous in elderly patients

›Dehydration from vomiting develops faster in elderly — lower threshold for IV hydration

›Medication considerations

›Meclizine: avoid per Beers Criteria — high anticholinergic burden; increased fall and confusion risk

10Background/b42

Epidemiology

›Prevalence and incidence

›Prevalence approximately 50–200 per 100,000 adults globally

›Incidence estimated at 7.5 per 100,000 per year in the United States

›Peak onset between ages 40–60 with biphasic occurrence in the 20s and 60s

›Slight female predominance

›Genetic factors

›Familial MD in approximately 10% of cases

›Autosomal dominant inheritance with incomplete penetrance

›Multiple gene loci implicated including FAM136A, DTNA, PRKCB

›Disease course

›Unilateral initially; up to 50% develop bilateral involvement over decades

›Attack frequency typically peaks early then decreases over approximately 8 years

›Hearing loss is progressive regardless of attack frequency

›Significant psychosocial disability — anxiety and depression common comorbidities

Pathophysiology

›Endolymphatic hydrops mechanism

›Abnormal accumulation of endolymph in the membranous labyrinth

›Increased endolymphatic pressure causes distension of scala media and saccule

›Rupture of Reissner's membrane allows mixing of endolymph and perilymph

›Sudden depolarization of hair cells causes acute vertigo attack

›Subsequent recovery of membrane integrity explains episodic nature

›Contributing mechanisms

›Impaired endolymph resorption via endolymphatic sac dysfunction

›Immune-mediated inner ear inflammation proposed in subgroup

›Viral trigger (herpes simplex virus reactivation) hypothesized

›Vascular dysregulation and inner ear microcirculation abnormalities

›Cochlear arteriole vasospasm may contribute to fluctuating hearing loss

11Patient Discharge Instructions/pdi32

copy discharge instructions

›Diagnosis and explanation

›You have been diagnosed with Meniere's disease, a chronic inner ear condition

›Meniere's disease causes episodes of spinning sensation (vertigo), hearing changes, ringing in the ear (tinnitus), and ear fullness

›There is no cure but symptoms can be managed and attacks can be reduced

›Medications prescribed

›Take the antiemetic or vestibular suppressant medication as directed — only during acute attacks

›Do not use vestibular suppressant medications continuously — they can prevent your brain from adjusting

›Continue any prescribed diuretic medication daily as directed

›Monitor for signs of low potassium on diuretics: muscle cramps, weakness, irregular heartbeat

›Diet and lifestyle

›Sodium restriction to less than 1,500–2,300 mg per day

›Reduce caffeine intake (coffee, tea, energy drinks, chocolate)

›Limit alcohol to no more than 1 drink per day

›Maintain consistent daily fluid intake — avoid large fluctuations

›Adequate sleep and stress management

›Activity restrictions

›No driving or operating heavy machinery during active vertigo — this is a safety requirement

›Return to normal activities between attacks when asymptomatic

›Falls risk is elevated — use handrails and avoid heights during active disease periods

›Follow-up appointments

›ENT or otolaryngology appointment within 2–4 weeks — mandatory for new diagnosis

›Audiology appointment for formal hearing test

›Keep a symptom diary: record attack dates, duration, triggers, and severity

›Return to emergency department immediately if

›New weakness, numbness, difficulty speaking or swallowing

›Vision loss or double vision

›Severe headache unlike previous headaches

12References/r22

Guidelines and key sources

›AAO-HNS 2020 Clinical Practice Guideline

›Basura GJ, Adams ME, Monfared A, et al. Clinical Practice Guideline: Meniere's Disease. Otolaryngology—Head and Neck Surgery. 2020

›Primary guideline for diagnosis, management, and stepwise treatment of Meniere's disease

›Establishes definite and probable MD diagnostic criteria

›Cochrane systematic reviews 2023

›Webster KE et al. Systemic Pharmacological Interventions for Meniere's Disease. Cochrane Database Syst Rev. 2023

›Webster KE et al. Lifestyle and Dietary Interventions for Meniere's Disease. Cochrane Database Syst Rev. 2023

›Hussain K, Murdin L, Schilder AG. Restriction of Salt, Caffeine and Alcohol Intake for the Treatment of Meniere's Disease. Cochrane Database Syst Rev. 2018

›ACR Appropriateness Criteria

›Wang LL, Thompson TA, Shih RY, et al. ACR Appropriateness Criteria: Dizziness and Ataxia: 2023 Update. J Am Coll Radiol. 2024

Supporting references

›HINTS exam validation

›Gottlieb M, Peksa GD, Carlson JN. Head Impulse, Nystagmus, and Test of Skew Examination for Diagnosing Central Causes of Acute Vestibular Syndrome. Cochrane Database Syst Rev. 2023

›Sensitivity 100%, specificity 96% for central cause in acute vestibular syndrome

›Pathophysiology and genetics

›Rizk HG, Mehta NK, Qureshi U, et al. Pathogenesis and Etiology of Meniere Disease: A Scoping Review. JAMA Otolaryngology. 2022

›Parra-Perez AM, Lopez-Escamez JA. Types of Inheritance and Genes Associated With Familial Meniere Disease. J Assoc Res Otolaryngol. 2023

›MRI for hydrops imaging

›Li J, Li L, Jin X, et al. MRI Can Help Differentiate Meniere's Disease From Other Menieriform Diseases. Scientific Reports. 2023

›Clinical reviews

›Wu V, Sykes EA, Beyea MM, et al. Approach to Meniere Disease Management. Canadian Family Physician. 2019

›Rogers TS, Noel MA, Garcia B. Dizziness: Evaluation and Management. American Family Physician. 2023

›Sajjadi H, Paparella MM. Meniere's Disease. Lancet. 2008

Learn More: Meniere's Disease→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed August 18, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.